Literature DB >> 3936263

Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases.

K Søndergaard, K Hou-Jensen.   

Abstract

486 patients with primary cutaneous malignant melanoma clinical stage I were examined in order to evaluate the prognostic importance of partial regression in thin lesions. All the melanomas measured 1 mm or less in maximal thickness. The study showed that past regression with fibrotic scar tissue adversely affected survival in patients with thin melanomas. The 10 year survival was 95% for patients without regression in contrast to 79% for patients with past regression. It was, furthermore, demonstrated that active regression without fibrotic scar tissue did not influence survival significantly. The wider and the thicker the fibrotic area, the poorer the survival. Although the prognostic importance of this finding was not statistically significant, we suggest that the horizontal width of the fibrotic area in particular may be a valuable prognostic guide in thin melanomas with past regression.

Entities:  

Mesh:

Year:  1985        PMID: 3936263     DOI: 10.1007/bf00707986

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  11 in total

1.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

2.  Spontaneous regression of melanoma.

Authors:  V J McGovern
Journal:  Pathology       Date:  1975-04       Impact factor: 5.306

3.  Experience of thin cutaneous melanomas (less than 0.76 mm and less than 0.85 mm thick) in a large plastic surgery unit: a 5 to 17 year follow-up.

Authors:  J C Briggs; N B Ibrahim; A G Hastings; R W Griffiths
Journal:  Br J Plast Surg       Date:  1984-10

4.  Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

5.  Metastases of thin melanomas.

Authors:  H Trau; D S Rigel; M N Harris; A W Kopf; R J Friedman; S L Gumport; R S Bart; W R Grier
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

6.  Prognosis in patients with thin malignant melanoma: influence of regression.

Authors:  V J McGovern; H M Shaw; G W Milton
Journal:  Histopathology       Date:  1983-09       Impact factor: 5.087

7.  Biologic behavior of thin malignant melanomas with regressive changes.

Authors:  R R Paladugu; R H Yonemoto
Journal:  Arch Surg       Date:  1983-01

8.  Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. A multivariate regression analysis.

Authors:  K Søndergaard; G Schou
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

9.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  11 in total

Review 1.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

2.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

3.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Authors:  Sook Jung Yun; Phyllis A Gimotty; Wei-Ting Hwang; Peter Dawson; Patricia Van Belle; David E Elder; Rosalie Elenitsas; Lynn Schuchter; Paul J Zhang; DuPont Guerry; Xiaowei Xu
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

5.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

7.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

8.  Morphometric, DNA and PCNA in thin malignant melanomas.

Authors:  V Björnhagen; E Månsson-Brahme; J Lindholm; A Mattsson; G Auer
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

9.  Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.

Authors:  A Håkansson; B Gustafsson; L Krysander; B Hjelmqvist; B Rettrup; L Håkansson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

10.  Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.

Authors:  A Håkansson; B Gustafsson; L Krysander; L Håkansson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.